Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Abbott India Limited (ABBOTINDIA.NS)
Mumbai, IN
Abbott India Limited is a pharmaceutical enterprise that conducts its operations across India. The company provides an extensive portfolio of medicinal products designed for a broad spectrum of therapeutic areas, including women's health, digestive conditions, metabolic disorders, central nervous system ailments, pain management, premature labor concerns, vitamin supplementation, sleep aids, immunizations, and general consumer health items. Established in 1944, the firm was formerly known as Knoll Pharmaceuticals Limited until it officially adopted the name Abbott India Limited in July 2002. Headquartered in Mumbai, India, it operates as a subsidiary of Abbott Capital India Limited.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.22% | +1.32% | +4.34% | +0.90% | -9.03% | -7.32% | -10.53% | +26.71% | +66.48% | +471.25% | +3,233.33% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | -1 |
| Buy | 4 | -1 |
| Hold | 1 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - General: +6.6%+9.6% ★ Q1'26: +6.7% (vs Q1'25)
-
EPS growth Drug Manufacturers - General: +18.2%+17.8% Q1'26: +7.6% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - General: +36.0%+18.3% Q1'26: +29.6% (vs Q1'25)
-
EBIT margin Drug Manufacturers - General: +19.4%+29.6% ★ Q1'26: +27.0% (vs Q1'25)
-
ROIC Drug Manufacturers - General: +10.2%+108.1% ★ Q1'26: +53.7% (vs Q1'25)
-
Share dilution Drug Manufacturers - General: +0.0%+0.0% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - General: -0.29×0.10× ★ Q1'26: 0.02× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2014 actual |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 5 Rev. Ana. 6 EPS Ana. |
Mar 2027 6 Rev. Ana. 7 EPS Ana. |
Mar 2028 6 Rev. Ana. 7 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
18.69B
est: 21.51B (-13.1%)
|
22.36B
est: 22.82B (-2.0%)
|
26.05B
est: 26.77B (-2.7%)
|
28.93B
est: 31.22B (-7.4%)
|
33.00B
est: 33.19B (-0.6%)
|
36.76B
est: 38.31B (-4.0%)
|
40.91B
est: 41.60B (-1.6%)
|
43.08B
est: 43.08B (0.0%)
|
49.10B
est: 48.95B (+0.3%)
|
53.47B
est: 54.29B (-1.5%)
|
58.47B
est: 58.58B (-0.2%)
|
64.07B
est: 63.70B (+0.6%)
|
69.18B
68.70B – 69.52B
+8.6% YoY
|
74.94B
71.96B – 76.85B
+8.3% YoY
|
81.71B
76.02B – 84.57B
+9.0% YoY
|
| EBITDA |
2.56B
est: 5.68B (-55.0%)
|
3.60B
est: 3.68B (-2.3%)
|
4.15B
est: 4.61B (-10.0%)
|
4.55B
est: 8.26B (-44.9%)
|
6.41B
est: 5.51B (+16.3%)
|
7.18B
est: 8.12B (-11.5%)
|
8.71B
est: 8.66B (+0.5%)
|
10.01B
est: 9.20B (+8.8%)
|
11.65B
est: 10.34B (+12.7%)
|
13.60B
est: 12.18B (+11.6%)
|
17.01B
est: 13.96B (+21.9%)
|
19.70B
est: 20.45B (-3.7%)
|
27.51B
27.32B – 27.65B
+34.5% YoY
|
29.80B
28.62B – 30.56B
+8.3% YoY
|
32.49B
30.23B – 33.63B
+9.0% YoY
|
| EBIT |
2.38B
est: 5.40B (-56.0%)
|
3.45B
est: 2.74B (+26.0%)
|
4.01B
est: 3.49B (+14.7%)
|
4.39B
est: 7.86B (-44.2%)
|
6.25B
est: 4.21B (+48.6%)
|
7.01B
est: 5.92B (+18.4%)
|
8.11B
est: 6.32B (+28.3%)
|
9.44B
est: 7.61B (+24.0%)
|
10.99B
est: 8.55B (+28.4%)
|
12.90B
est: 10.08B (+27.9%)
|
16.30B
est: 11.55B (+41.1%)
|
18.98B
est: 24.82B (-23.5%)
|
26.89B
26.70B – 27.02B
+8.3% YoY
|
29.13B
27.97B – 29.87B
+8.3% YoY
|
31.76B
29.55B – 32.87B
+9.0% YoY
|
| Net Income |
1.67B
est: 1.93B (-13.5%)
|
2.29B
est: 2.13B (+7.6%)
|
2.55B
est: 2.65B (-3.6%)
|
2.77B
est: 3.25B (-15.0%)
|
4.01B
est: 3.02B (+33.0%)
|
4.50B
est: 4.62B (-2.6%)
|
5.93B
est: 4.80B (+23.6%)
|
6.91B
est: 6.39B (+8.1%)
|
7.99B
est: 7.18B (+11.3%)
|
9.49B
est: 8.46B (+12.2%)
|
12.01B
est: 9.69B (+23.9%)
|
14.14B
est: 14.07B (+0.5%)
|
15.71B
15.41B – 15.96B
+11.6% YoY
|
17.37B
16.43B – 17.92B
+10.6% YoY
|
19.41B
17.61B – 20.48B
+11.8% YoY
|
| SGA |
5.54B
est: 1.69B (+228.8%)
|
4.00B
est: 6.68B (-40.1%)
|
4.44B
est: 7.08B (-37.2%)
|
4.52B
est: 2.45B (+84.1%)
|
5.32B
est: 7.82B (-31.9%)
|
6.02B
est: 9.25B (-34.9%)
|
6.23B
est: 9.75B (-36.1%)
|
6.13B
est: 10.01B (-38.8%)
|
7.36B
est: 11.25B (-34.6%)
|
6.85B
est: 13.26B (-48.3%)
|
6.91B
est: 15.19B (-54.5%)
|
6.93B
est: 8.26B (-16.1%)
|
8.94B
8.88B – 8.99B
+8.3% YoY
|
9.69B
9.31B – 9.94B
+8.3% YoY
|
10.57B
9.83B – 10.94B
+9.0% YoY
|
| EPS |
78.47
est: 90.67 (-13.5%)
|
107.75
est: 113.94 (-5.4%)
|
120.12
est: 132.55 (-9.4%)
|
130.19
est: 152.60 (-14.7%)
|
188.81
est: 186.10 (+1.5%)
|
211.93
est: 218.53 (-3.0%)
|
279.04
est: 302.41 (-7.7%)
|
325.04
est: 332.90 (-2.4%)
|
375.87
est: 376.12 (-0.1%)
|
446.80
est: 457.50 (-2.3%)
|
565.30
est: 563.33 (+0.3%)
|
665.62
est: 651.32 (+2.2%)
|
739.10
725.00 – 750.90
+13.5% YoY
|
817.25
773.01 – 843.07
+10.6% YoY
|
913.36
828.68 – 963.85
+11.8% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | A | 4/5 | 5/5 | 5/5 | 5/5 | 4/5 | 2/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Kartik Rajendran | MD & Director | — | male |
| Maithilee Mistry | Chief Financial Officer | — | female |
| Sangeeta Mukesh Shetty | Associate Director - Secretarial, Company Secretary, Nodal Officer & Compliance Officer | — | female |
| Vinutha Mufti | Director of Business Human Resources | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ABBOTINDIA.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
